Erythropoietin: Back to basics

Blood

Volumn 115, Issue 21, 2010, Pages 4151-4152

  Jelkmann, Wolfgang ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; MESSENGER RNA; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANDROGEN THERAPY; ANGIOGENESIS; APOPTOSIS; CANCER GROWTH; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CELL PROTECTION; CELL SURFACE; CELL SURVIVAL; CHRONIC KIDNEY DISEASE; COGNITION; CYTOTOXICITY; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEMATOCRIT; HEMATOPOIESIS; HEMODIALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IN VIVO STUDY; KIDNEY TRANSPLANTATION; KIDNEY TUBULE CELL; NOTE; OUTCOME ASSESSMENT; PLEIOTROPY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEIN BINDING; QUALITY OF LIFE; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; TUMOR CELL;

EID: 77956397310     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-271395     Document Type: Note

References (11)

1. Sinclair AM, Coxon A, McCaffery I, et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood. 2010;115(21):4264-4272.
2. Swift S, Ellison AR, Kassner P, et al. Absence of functional EpoR expression in human tumor cell lines. Blood. 2010;115(21):4254-4263 .
3. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989;35(1):134-148. (Pubitemid 19047434)
4. Unger EF, Thompson AM, Blank MJ, et al. Erythropoiesis- stimulating agents-time for a reevaluation. N Engl J Med. 2010;362(3):189-192.
5. Silverberg DS, Iaina A, Wexler D, Blum M. The pathological consequences of anaemia. Clin Lab Haematol. 2001;23(1):1-6.
6. Elliott S, Busse L, McCaffery I, et al. Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells. J Immunol Methods. 2010;352(1-2):126-139.
7. Jelkmann W, Depping R, Metzen E. Nonhematopoietic effects of erythropoiesis-stimulating agents. In: Elliott SG, M Foote M, Molineux G, eds. Erythropoietins, Erythropoietic Factors, and Erythropoiesis. 2nd ed. Basel, Birkhäuser: 2009: 299-317.
8. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol. 2008;67(1):39-61.
9. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis- stimulating agents in oncology: a study-level metaanalysis of survival and other safety outcomes. Br J Cancer. 2010;102(2):301-315.
10. Ehrenreich H, Weissenborn K, Prange H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40(12):e647-e656.
11. Jelkmann W. Developments in the therapeutic use of erythropoiesis stimulating agents. Br J Haematol. 2008;141(3):287-297. Erratum in Br J Haematol. 2008;143(5):757.